Molecular imaging firm Blue Earth Diagnostics has signed an agreement for exclusive rights to radiopharmaceutical technology firm Scintomic's "radiohybrid" prostate-specific membrane antigen (rhPSMA-7) imaging agent.
The rhPSMA-7 imaging compound is capable of targeting and labeling prostate cancer cells in conjunction with either PET imaging radiopharmaceuticals such as Blue Earth's Axumin (fluciclovine F-18) or therapeutic radioisotopes such as lutetium-177 (Lu-177), according to the company. This potentially allows for rhPSMA-7 to facilitate both imaging and therapy for prostate cancer.
Blue Earth plans to continue developing rhPSMA-7 and to collaborate with Scintomics on optimizing its therapeutic applications for prostate cancer therapy.
